登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600962 证券简称：国投中鲁 公告编号：2025-063 国投中鲁果汁股份有限公司 关于本次交易摊薄即期回报情况及填补措施的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 国投中鲁果汁股份有限公司（以下简称国投中鲁或公司）拟通过发行股份向国家开发投资集团有限公司 （以下简称国投集团）、宁波市新世达壹号管理咨询合伙企业（有限合伙）、国家集成电路产业投资基 金二期股份有限公司、广州产投建广股权投资合伙企业（有限合伙）、广州湾区智能传感器产业集团有 限公司、科改策源（重庆）私募股权投资基金合伙企业（有限合伙）、国华军民融合产业发展基金（有 限合伙）购买其合计持有的中国电子工程设计院股份有限公司（以下简称电子院）100%股份，并向不 超过35名特定投资者发行股份募集配套资金（以下简称本次交易）。 根据《国务院办公厅关于进一步加强资本市场中小投资者合法权益保护工作的意见》（国办发 [2013]110号）、《国务院关于进一步促进资本市场健康发展的若干意见》（国发[201 ...

Group 1 - The core point of the article is that Mingde Biology plans to acquire 100% equity of Wuhan Bikaier for cash, which is expected to be a significant asset restructuring but will not involve a restructuring listing or share issuance [2][3] - The acquisition aligns with Mingde Biology's strategic focus on critical care business development, as Wuhan Bikaier is a leading company in emergency protection, serving high-quality industrial clients and expanding into the household consumer market [3] - The integration is expected to enhance Mingde Biology's critical care diagnosis and treatment ecosystem, improving asset quality and profitability while strengthening its market position in the critical care sector [3] Group 2 - For the first three quarters of 2025, Mingde Biology reported total revenue of 227 million yuan, a year-on-year increase of 0.53%, but net profit decreased by 83.30% to 13.52 million yuan [4] - The accounts receivable balance reached 653 million yuan, significantly exceeding revenue, indicating cash collection pressure post-pandemic [4][5] - The company’s revenue from in vitro diagnostics for the first three quarters of 2025 was 90.60 million yuan, accounting for 65.04% of total revenue, but the industry is facing a transformation period [8][9]

Core Viewpoint - Zhongneng Electric (300062) announced the termination of a major asset restructuring plan to acquire 65% equity of Shandong Dacheng Electric Co., Ltd. and related debts, as the bidding process concluded with other qualified buyers winning the auction [1][2]. Group 1: Announcement Details - The board of Zhongneng Electric held meetings on December 5 and December 23, 2025, to approve the proposal for participating in the auction of the equity and debts of Shandong Dacheng Electric and related companies [1]. - The company aimed to enhance its competitive position by expanding its product offerings from medium voltage to high voltage through this acquisition [1]. - The decision to terminate the restructuring was made after careful due diligence and discussions with intermediaries, concluding that the company would not participate in the bidding and had not paid any deposit [2]. Group 2: Impact and Future Plans - The termination of the asset restructuring will not adversely affect the company's normal business operations or the interests of minority shareholders [2]. - The company will continue to pursue its strategic objectives and manage its operations in an orderly manner [2]. - Zhongneng Electric committed to not planning any major asset restructuring within one month following the announcement [2]. Group 3: Market Performance - The latest stock price of Zhongneng Electric is reported at 9.08 CNY per share, with a total market capitalization of 5.72 billion CNY [3]. - The stock experienced a trading volume of 611,400 hands and a turnover rate of 13.34% [4].

Group 1 - The company announced the termination of a major asset restructuring plan to acquire 65% equity of Shandong Dacheng Electric Co., Ltd. and related debts [2][3] - The decision to terminate the restructuring was made after careful due diligence and communication with relevant intermediaries, concluding that the company would not participate in the bidding process [3] - The company has not signed any agreements related to this major asset restructuring and does not face any breach of contract liabilities [3] Group 2 - The company's latest stock price is reported at 9.08 yuan per share, with a total market capitalization of 5.72 billion yuan [4]

Group 1 - The core point of the article is that Mingde Biological has signed a framework agreement with Bluefan Medical to acquire 100% equity of Wuhan Bikaier Rescue Supplies Co., Ltd. in a cash transaction, which will make the target company a wholly-owned subsidiary after completion [1][3]. - The transaction is expected to constitute a major asset restructuring as defined by the regulations, and it will not involve a restructuring listing or the issuance of shares [3]. - The target company specializes in emergency rescue products and has a strong foundation in both industrial emergency protection and consumer markets, which complements Mingde Biological's existing business in critical care diagnostics [4]. Group 2 - Mingde Biological aims to enhance its strategic focus on critical care business through this acquisition, which will help extend its integrated diagnostic and rescue services from medical institutions to industrial and household scenarios [4]. - The company has a comprehensive product matrix supported by ten technology platforms, covering various diagnostic product lines and providing services to over 7,500 medical institutions across China and more than 50 countries [3]. - The current stock price of Mingde Biological is reported at 17.82 yuan per share, with a total market capitalization of 4.144 billion yuan [6].

公司股票将于2025年12月31日(星期三)开市起复牌。 智通财经APP讯，东杰智能(300486.SZ)发布公告，此前披露，公司拟以发行股份及支付现金的方式购买 山东齐康智合创业投资管理有限公司等交易对方合计持有的遨博(北京)智能科技股份有限公司(以下简 称"遨博智能"或"标的公司")控股权并配套募集资金。经审慎研究，公司决定终止筹划本次重大资产重 组事项。 ...

格隆汇12月30日丨东杰智能(300486.SZ)公布，公司于2025年12月17日披露了《东杰智能科技集团股份 有限公司关于筹划发行股份及支付现金购买资产并募集配套资金暨关联交易事项的停牌公告》（公告编 号：2025-160），公司拟以发行股份及支付现金的方式购买山东齐康智合创业投资管理有限公司等交易 对方合计持有的遨博（北京）智能科技股份有限公司（简称"遨博智能"或"标的公司"）控股权并配套募 集资金。经审慎研究，公司决定终止筹划本次重大资产重组事项。 责任编辑：钟离 财经频道更多独家策划、专家专栏，免费查阅>> 筹划本次重大资产重组以来，公司及相关各方严格按照相关法律法规的要求，积极推动本次重大资产重 组相关的各项工作，与本次重大资产重组的交易对方进行了积极磋商和沟通。经充分研究相关方意见， 积极磋商和认真探讨后，认为公司目前实施重大资产重组的条件尚未完全成熟。为切实维护公司及全体 股东利益，经公司审慎研究，决定终止筹划本次重大资产重组事项。公司股票将于2025年12月31日（星 期三）开市起复牌。 ...

Core Viewpoint - Mingde Biological has signed a framework agreement with Bluefan Medical to acquire 100% equity of Wuhan Bikaier Rescue Supplies Co., Ltd., marking a significant asset restructuring initiative aimed at enhancing its emergency medical services business [1][3][4]. Group 1: Transaction Details - The transaction is expected to constitute a major asset restructuring as defined by the regulations, and it will be executed in cash without involving a share issuance or changing the controlling shareholder [3][4]. - The target company specializes in emergency rescue products, particularly first aid kits, and has a strong presence in both industrial and consumer markets [3][4]. Group 2: Strategic Importance - This acquisition aligns with Mingde Biological's strategic focus on the critical care sector, allowing for an integrated approach to emergency diagnosis and treatment, thereby enhancing its market position [4]. - The integration of product lines and customer bases between Mingde Biological and the target company is expected to create a synergistic ecosystem that spans diagnosis, protection, and treatment [4]. Group 3: Current Status and Market Information - The transaction is still in the planning stage, with ongoing negotiations and due diligence, and the final terms will be established in a formal acquisition agreement [4][5]. - As of the latest market data, Mingde Biological's stock price is reported at 17.82 yuan per share, with a total market capitalization of 4.144 billion yuan [6].

Core Viewpoint - Mingde Biological has signed a framework agreement with Bluefan Medical to acquire 100% equity of Wuhan Bikaier Rescue Supplies Co., Ltd., marking a significant strategic move towards enhancing its capabilities in emergency medical services [1][3]. Group 1: Transaction Details - The transaction is expected to constitute a major asset restructuring as defined by the regulations, and it will be executed in cash without involving share issuance [3]. - The acquisition does not involve related party transactions and will not lead to changes in the controlling shareholder or actual controller of Mingde Biological [3]. - The target company specializes in emergency rescue products, particularly first aid kits, and has a strong presence in both industrial and consumer markets [3][4]. Group 2: Strategic Importance - This acquisition aligns with Mingde Biological's strategic focus on the critical care sector, allowing for an integrated approach to emergency diagnosis and treatment [4]. - The complementary nature of the product lines and customer bases between Mingde Biological and the target company is expected to enhance market positioning and competitiveness in the emergency medical field [4]. Group 3: Market Information - Mingde Biological's latest stock price is reported at 17.82 yuan per share, with a total market capitalization of 4.144 billion yuan [6].

自公司首次披露拟参与竞拍股权暨重大资产重组的提示性公告后，各方均积极推进本次重组的相关工 作，但经审慎尽职调查及公司与相关中介机构充分沟通论证后，经公司审慎研究，决定不参与标的公司 本轮股权及债权竞拍事宜，公司也未缴纳保证金。标的公司本轮公开挂牌程序已按期结束，且标的公司 已由其他合格竞买方摘牌受让，据此，公司决定终止筹划本次交易事项。 格隆汇12月30日丨中能电气(300062.SZ)公布，公司分别于2025年12月5日、2025年12月23日召开第六届 董事会第三十次会议及2025年第一次临时股东大会，审议通过《关于参与竞拍山东达驰电气有限公司、 山东达驰高压开关有限公司、水发驰翔电气（山东）有限公司65%股权及转让方对标的企业享有的债权 的议案》。为深度契合公司产品由中压向高压领域延伸的战略布局，突破高压核心技术与市场资源壁 垒，提升公司综合竞争水平，公司拟通过在山东产权交易中心摘牌并支付现金的方式收购山东达驰电气 有限公司、山东达驰高压开关有限公司、水发驰翔电气（山东）有限公司65%股权及转让方对标的企业 享有的债权。交易对方为山东城翔产业投资合伙企业（有限合伙）、山东水发电力集团有限公司。股东 大会 ...